Zenas BioPharma to present MS data at MSToronto2026
Zenas BioPharma said it will present orelabrutinib data in relapsing remitting multiple sclerosis, trial designs in progressive multiple sclerosis and other portfolio data at MSToronto2026.
Zenas BioPharma said it will present orelabrutinib data in relapsing remitting multiple sclerosis, trial designs in progressive multiple sclerosis and other portfolio data at MSToronto2026.